Loading

JSM Atherosclerosis

Neurotrophin Expression in Chagasic Megacolon

Research Article | Open Access

  • 1. Parasitology Sector, Universidade Federal de Uberlândia, Brazil
  • 2. Neurosciences Laboratory, Universidade Federal de Uberlândia, Brazil
  • 3. Department of Surgery, Universidade Federal de Goiás, Brazil
  • 4. Institute of Anatomy I, University of Erlangen–Nuremberg, Germany
+ Show More - Show Less
Corresponding Authors
Alexandre Barcelos Morais da Silveira, Neurosciences Laboratory, Universidade Federal de Uberlândia, Module 2A, ICBIM, Campus Umuarama, Brazil, Tel: 55 34 99682-5467.
Abstract

Patients with chagasic megacolon exhibit lesions of the enteric nervous system (ENS), associated with the inflammatory process and, some substances, like neurotrophins, may restrict neuronal destruction levels. The objective of this study was to characterize the neurotrophins expression in tissues from chagasic patients and verify its involvement in megacolon development. We used colon samples from chagasic patients with and without megacolon and non-infected individuals that, after preparation, were submitted to confocal fluorescence immunohistochemistry. To identify the sources and expression level of neurotrophins Nerve growth factor (NGF), Glial cell-derived neurotrophic factor (GDNF), and Neurotrophin-3 (NT-3), we performed a co-localization with a neuronal marker (Calretinin) and glial cell marker (S-100). Our results pointed that enteroglial cells are the main sources of neurotrophins in all analyzed groups. Besides, chagasic patients without megacolon presented high expression of all investigated neurotrophins when compared with chagasic patients with megacolon and with non-infected individuals. This data suggest that neurotrophins might perform a protective function in ENS due an inflammatory process and prevent the megacolon installation. By the other side, chagasic patients that do not express an adequate level of neurotrophins may evolve to megacolon form. We believe that drugs administration qualified to elevate neurotrophins levels in the intestine could prevent the megacolon installation and maintain the normal function of the gastrointestinal tract.

Citation

de Freitas MAR, Segatto N, Remolli PF, de Oliveira EC, Brehmer A, da Silveira AB (2016) Neurotrophin Expression in Chagasic Megacolon JSM Atheroscler 1(3): 1013.

Keywords

•    Chagas’ disease
•    Chagasic megacolon
•    Neurotrophins
•    Enteric nervous system

ABBREVIATIONS

NGF: Nerve Growth Factor; GDNF: Glial Cell-Derived Neurotrophic Factor; NT-3: Neurotrophin-3; ENS: Enteric Nervous System

INTRODUCTION

Chagas´ disease represents a substantial health and socioeconomic problem in several countries. In particular, affects 8-10 million people in the Americas, with an additional 40 million people at risk [1]. Chagas´ disease exhibits two clinical phases: acute and chronic. The acute phase occurs after infection, beginning when the parasite enters the mammalian host. This phase may appear asymptomatic or accompanied by nonspecific symptoms such as fever, asthenia, and headache [2]. The chronic phase, mainly, may last for the patient’s entire lifetime. It begins with the decline of parasitemia and absence of symptoms. Even after the nonspecific symptoms, some organs may still be affected, such as the gastrointestinal tract, taking the form of two main syndromes: megaesophagus that leads to dysphagia and regurgitation, and megacolon, conducting to severe constipation and fecal retention [3]. Both megaesophagus and megacolon show strong cellular and humoral immune responses. The mechanisms underlying the transition from asymptomatic to symptomatic are still unclear, but numerous factors must be involved, such as differences in parasite strain, parasite load, infection time, host genetic background and immune response [4-6].

Recent reports about chagasic megacolon suggest that disturbance of immune system and enteric nervous system (ENS) has also been associated with the development of gastrointestinal forms [7-9]. Some substances act in both systems and the most important class are the neurotrophic factors or neurotrophins. Neurotrophins are important for neuronal survival and development. It is accepted that these substances may represent a link between the nervous and immune systems and some studies demonstrated that an unsteadiness of neurotrophins may arise during inflammatory processes [10]. Neurotrophins include nerve growth factor (NGF), glial-derived neurotrophic factor (GDNF) and neurotrophin-3 (NT-3). NGF concentration in human intestine is associated with increased inflammatory process in several diseases. GDNF act stimulating the outgrowth of neuronal projections, neuronal differentiation and are able to protect neurons from apoptosis under various conditions, while NT3 mediates growth of human intestinal mast cell, which is known to participate in the regulation of gastrointestinal motility [11-13].

It has been suggested that these neurotrophins may play an important role in the pathophysiology of Chagas´ disease, as was demonstrated in other gastrointestinal diseases like ulcerative colitis and inflammatory bowel disease [14-17]. However, neurotrophins involvement in the development of chagasic megacolon is not determinate. To elucidate this, the aim of this study was to analyze and compare the neurotrophins expression and its´ relation with neuronal and enteroglial cells in colon samples from chagasic patients with and without chagasic megacolon and non-infected individuals.

MATERIALS AND METHODS

Patients and samples

Colon tissue samples were collected from chagasic patients with megacolon (n=12), chagasic patients without megacolon (n=12) and non-infected individuals (n=12). All chagasic patients have been followed for many years due to Chagas disease infection and were enrolled in this study because they developed only the megacolon clinical form. Patients were not matched in terms of age, gender or ethnic origin. Reasons for tissue resection were colon complications caused by Chagas’ disease whilst noninfected individuals had adenocarcinoma or diverticular disease as the main reasons. All surgical specimens were collected from the same topographic region of the colon (rectum and sigmoid) and patients were submitted to low anterior resection or Duhamel surgical procedure. The use of human tissues for these experiments was approved by the Ethics Committee of the University of Erlangen-Nuremberg as well as the Human Ethics Committee of the Federal University of Uberlândia (Brazil).

Samples were collected from dilated segment and they had, at least, 4 cm of length and the tissue circumference was variable according to the amount of dilatation. The samples were rinsed with phosphate buffered saline (pH 7.2-7.4) and fixed. During fixation, the gut samples were distended with fixative solution (freshly diluted solution of 4% paraformaldehyde in phosphatebuffered saline - pH 7.2-7.4) using a syringe. Then, the inflated segments were placed in the fixative solution for 2-4 h. After this time, the inflated segment was opened, separated into small pieces and stored in 0,05 % thimerosal in 0,1 M phosphate buffered saline (pH 7.2-7.4) at 4° C. Alternately, short segments were pinned out in a Sylgardlined Petri dish and transferred to 4% formalin in 0.1 M phosphate buffer (pH 7.4) at room temperature for 2–3 h. After several washes in 0.05 M TRIS-buffered saline (TBS; pH 7.4), three longitudinal muscle/myenteric plexus whole mounts (2 cm length, 1 cm width) per segment (derived from each patient) were prepared. The following day, the small segments of tissue were transferred to a mixture of PBS-sucrose-azide and OCT (Optimal Cutting Temperature) compound (Tissue Tek, Elkhart, IN, USA) at a ratio of 1:1 for a further 24 hours before being embedded in 100% OCT. Sections 12 μm thick were cut and mounted on microscope slides and dried for 1 hour at room temperature.

Immunohistochemical investigation

Triple-staining immunohistochemistry was conducted combining the neuronal marker peripherin and S-100 (panglial marker) antibodies with neurotrophin. Details of primary antibodies are listed in (Table 1). The specificity of antibodies to their targets has been proven by several previous works (18- 22). Sections were first incubated in 10% normal donkey serum (NDS) plus 1% v/v Triton X-100 for 1h. Incubation with primary antibodies was carried out for 24 hours at 4° C with diluted antiserum containing 10% NDS. Double or Triple-labeling was achieved using a combination of Peripherin and S-100 with NGF, GDNF and NT3 markers. Following incubation in primary antiserum, preparations were rinsed in PBS (3 × 10 min) and then incubated for 1 hour at room temperature with secondary antibodies (Donkey anti-goat, donkey anti-mouse and donkey anti-rabbit, dilution 1:1000, Molecular Probes, Germany). Further 3 × 10-min washes in PBS were done before the tissue was mounted in fluorescence mounting medium.

The analysis was performed considering the specifically labeled area of, at least, 10 neuronal ganglia per patient in both the submucosal and the myenteric plexuses. Prior to incubation, they were viewed by using a confocal laser scanning microscope (Nikon Eclipse E1000-M, Tokyo, Japan) equipped with a confocal system (Nikon Digital Eclipse C1) with three channels (laser configuration: 488 nm argon laser, 543 nm helium-neon laser [both from Melles Griot, Carlsbad, Calif., USA], 638 nm diode laser [Coherent, Santa Clara, Calif., USA]). A 20× dry objective lens (numerical aperture: 0.75) was used with the zoom factor set to 2.0 in all scanning sessions. Pinhole and gain were adjusted equally in all negative control sessions and values were noted. The images were created using three different excitation wavelengths and the figures plates were prepared using the EZ-C1 FreeViewer program (Gold Version 3.30 build 647) from Nikon Corporation.

Anti-peripherin, a very used intestinal pan-neuronal marker, and anti-S-100, that shows strong cross-reactivity against human enteroglial cells, were used to determine the co-localization between neurotrophins and neuronal or enteroglial components. Sections through ganglia were selected randomly in a meandering fashion until a total of 3 mm2 were analyzed in each ganglionated plexus. Single optical section images on the same focus plane were created in the ganglia by applying 2 different excitation wavelengths (488 nm argon laser, 543 nm heliumneon laser) Pictures were prepared using Confocal Assistant 4.02 and CorelDraw 13. For area analysis of reactive structures, the pictures were analyzed individually and merged, and the positive area was counted in square micrometer.

Statistics

Statistical analyses were conducted based on the nonparametric ANOVA-ONE WAY test, with the goal of detecting differences between the groups of patients. The significance level was p < 0.05 and all analyses were performed using the GraphPad Prim 3.0 software (San Diego, CA). The distribution of frequencies of all the variables and the measures of central tendency were calculated using various parameters: average, mean, percentiles, standard deviation. The associations between the dependent and independent variables were tested through bivariate and multivariate regression techniques (simple linear regression, multiple or logistical regression, according to the characteristics of the variable).

Table 1: Primary and secondary antibodies.

PrimaryAntibody Source Company Code SecondaryAntibody
Anti humanPeripherin Goat Santa Cruz Biotechnology SC-7604 ALEXA Fluor 488 Donkey antigoat
Anti human S-100 Mouse DAKO Ink Z-0311 ALEXA Fluor 488 Donkey antimouse
Anti human NGF Mouse Santa Cruz Biotechnology SC-549 ALEXA Fluor 555 Donkey antimouse
Anti human GDNF Mouse Santa Cruz Biotechnology SC-13147 ALEXA Fluor 555 Donkey antimouse
Anti human NT3 Mouse Santa Cruz Biotechnology SC-33907 ALEXA Fluor 555 Donkey antimouse

 

RESULTS AND DISCUSSION

Peripherin and S-100 expression

The quantitative data of peripherin and S-100 expression demonstrated that compared with non-infected individuals and chagasic patients without megacolon, chagasic patients with megacolon presented an intense denervation process that was revealed by peripherin immunoreactive area analysis. Besides, it was observed that while chagasic patients with megacolon showed enteroglial cells loss, chagasic patients without megacolon demonstrated increased expression of these cells. This data is according to with previous studies that demonstrated the denervation process in chagasic patients with megacolon [6,7,23].

Peripherin/ s-100/ neurotrophins immunoreactions

The co-localization of peripherin, S-100 and neurotrophins antibodies demonstrated that all analyzed neurotrophins (GDNF, NGF and NT3) were concentrated mainly in the neuronal plexuses in relation with the muscle layers in chagasic patients and noninfected individuals. However, when we compared both neuronal plexuses (submucosal and myenteric) there was no difference in proportional concentration between these two substances. The neurotrophins expression analysis showed that GDNF are NGF expressed mainly by neurons and, enteroglial cells present all neurotrophins in lower levels (Figure 1,2).

Quantitative data of neurotrophins expression was performed by a relative proportion between neurotrophins (GDNF, NGF and NT3 area) and neurons (peripherin area). Our results indicated that chagasic patients without megacolon have an increased expression statistically relevant of all studied neurotrophins (GDNF, NGF and NT3) compared with non-infected individuals and with chagasic patients with megacolon (Table 2).

DISCUSSION

A central finding in the present study was the characterization of the neurotrophins in samples from chagasic patients with megacolon and non-infected individuals. This is the first study to evaluate the relation between neuronal destruction, enteroglial loss, and distribution of neurotrophins in patients with chagasic megacolon. Our previous data indicated that chagasic patients with megacolon present high level of inflammation, and this process leads to denervation and destruction of the glial component in the intestine [7,24]. Besides, we demonstrated that colon from chagasic patients increased the levels of GAP-43 during neuronal destruction process [25]. We believe that the high level of GAP-43 indicates an attempt to recover the damaged components or even avoid a bigger loss in the enteric nervous system cells.

In the last years, a study using the culture of enteroglial cells determined that under inflammatory conditions, the glial cells increase the production of neurotrophins [14]. This data corroborates with our results because the same increased level of neurotrophins was found in enteroglial cells of chagasic patients without megacolon. Our results confirmed that, as much as enteroglial cells, neurons are important sources of neurotrophins. It was observed that the neurotrophins production is concentrated in the neuronal plexuses (submucosal and myenteric) and both neurons and enteroglial cells participate in this process.

It´s reasonable to suggest that the neuronal recovery should be made by neurotrophic factors, but it was necessary to identify them, their sources and where they should act. This study allowed us to infer how the enteric nervous system behaves under megacolon development, and only in Chagas disease we can observe a denervation process in the intestine caused by a parasite infection. Today, around 11 million of people are infected by T. cruzi and they are able to develop the chagasic megacolon anytime [26]. Besides, understanding Chagas disease will allow us to comprehend other intestinal diseases and maybe point new and more effective targets to treatment.

In the last decades, it was demonstrated that immune system has an important role in the chagasic megacolon development. It was previously demonstrated that the inflammatory process presented in chagasic megacolon is constituted mainly by lymphocytes, macrophages, eosinophils and mast cells [4,23,27,28]. It was showed that the higher inflammatory process, the higher the neuronal loss and the megacolon severity. Most of these immune cells are sources of neurotrophins, and because of this, we may suggest that although they act promoting an inflammatory process to destroy the parasite in the tissue, they also secret neurotrophins as an attempt to save as many neurons as possible [29]. We can observe in Figure (1,2) some spots of neurotrophins around neuronal ganglia that do not match with neurons or enteroglial cells. These spots are probably immune cells producing neurotrophins. However, just small concentrations of neurotrophins are out of neuronal ganglia, what suggest that immune cells alone are not enough to produce a satisfactory amount of neurotrophins. We conclude that although the enteric nervous system acts as the main source of neurotrophins, it needs the immune system cooperation to fulfill the role of repairing the neural loss.

We believe that to know the expression pattern of neurotrophins and their receptors in ENS of patients with chagasic megacolon can identify key components that provide protection to neurons as well as the components that do not actively participate in its protection. As an example, we suggest the activation of TrkA and TrkB receptors by activating substances or use neurotrophins synergist drug, which could actually increase the levels of regeneration ENS. From these data, we are certain that we will be able to suggest new treatment modalities that address both patient recovery and prevention of worsening of his states.

Table 2: Mean of Peripherin, S-100 and neurotrophins immunoreactive area in neuronal plexuses of chagasic patients and non-infected individuals.
(a) Statistically significant difference between this group and non-infected individual
(b) Statistically significant difference between this group and chagasic patients without megacolon; (p < 0.05)

Groups / neurotrophins                Peripherin                           S-100                      GDNF                         NGF
Submucosalplexus Mientericplexus Submucosalplexus Mientericplexus Submucosalplexus Mientericplexus Submucosalplexus Mientericplexus
Non-infectedindividuals 310 ± 29 344 ± 36 287 ± 22 301 ± 40 246 ± 20 243 ± 18 190 ± 29 186 ± 23
Chagasic patientswithout megacolon 286 ± 21 308 ± 33 415a ± 41 466a ± 47 512a ± 36 498a ± 28 417a ± 28 391a ± 31
Chagasic patientswith megacolon 197ab ± 21 144ab ± 15 188ab ± 17 214ab ± 23 268ab ±32 206b ± 35 178b ± 24 154b ± 28

 

CONCLUSION

Our results demonstrated that a relationship exists between the expression of neurotrophins on the gastrointestinal tract and the intensity of the inflammatory process in Chagas’ disease. Although it was established that Chagas disease patients with high expression of neurotrophins remain asymptomatic than those who do not have this adaptation. We believe that future studies will guide us for the immunomodulation of the gastrointestinal tract based on neurotrophin expression, which will allow us to prevent and treat a variety of inflammatory bowel disease.

ACKNOWLEDGEMENTS

This work was supported by funds from CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico), and Deutsche Forschungsgemeinschaft.

REFERENCES

1. Dias JC. Chagas disease in a life story: unveiling the disease, changing the world. Interview with Joao Carlos Pinto Dias. Interview by Roberto Briceno-Leon. Cad Saude Publica. 2009; 1: 179-186.

2. Köberle F. Chagas’ disease and Chagas’ syndromes: the pathology of American trypanosomiasis. Adv Parasitol. 1968; 6: 63-116.

3. KOBERLE F. [Pathology and pathological anatomy of Chagas’ disease]. Bol Oficina Sanit Panam. 1961; 51: 404-428.

4. da Silveira AB, Adad SJ, Correa-Oliveira R, Furness JB, D’Avila Reis D. Morphometric study of eosinophils, mast cells, macrophages and fibrosis in the colon of chronic chagasic patients with and without megacolon. Parasitology. 2007; 134: 789-796.

5. da Silveira AB, Arantes RM, Vago AR, Lemos EM, Adad SJ, CorreaOliveira R, et al. Comparative study of the presence of Trypanosoma cruzi kDNA, inflammation and denervation in chagasic patients with and without megaesophagus. Parasitology. 2005; 131: 627-634.

6. da Silveira AB, D’Avila Reis D, de Oliveira EC, Neto SG, LuquettiAO, Poole D, et al. Neurochemical coding of the enteric nervous system in chagasic patients with megacolon. Dig Dis Sci. 2007; 52: 2877-2883.

7. da Silveira AB, Freitas MA, de Oliveira EC, Neto SG, LuquettiAO, Furness JB, et al. Glial fibrillary acidic protein and S-100 colocalization in the enteroglial cells in dilated and nondilated portions of colon from chagasic patients. Hum Pathol. 2009; 40: 244-251.

8. Dutra WO, Menezes CA, Villani FN, da Costa GC, da Silveira AB, Reis D, et al. Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease. Mem Inst Oswaldo Cruz. 2009; 104: 208-218.

9. Jabari S, da Silveira AB, de Oliveira EC, Neto SG, Quint K, Neuhuber W, et al. Partial, selective survival of nitrergic neurons in chagasic megacolon. Histochem Cell Biol. 2011; 135: 47-57.

10. Lin A, Lourenssen S, Stanzel RD, Blennerhassett MG. Selective loss of NGF-sensitive neurons following experimental colitis. Exp Neurol. 2005; 191: 337-343.

11. Weinkauf C, Pereiraperrin M. Trypanosoma cruzi promotes neuronal and glial cell survival through the neurotrophic receptor TrkC. Infect Immun. 2009; 77: 1368-1375.

12. Boesmans W, Gomes P, Janssens J, Tack J, VandenBerghe P. Brainderived neurotrophic factor amplifies neurotransmitter responses and promotes synaptic communication in the enteric nervous system. Gut. 2008; 57: 314-322.

13. von Boyen GB, Steinkamp M, Geerling I, Reinshagen M, Schafer KH, Adler G, et al. Proinflammatory cytokines induce neurotrophic factor expression in enteric glia: a key to the regulation of epithelial apoptosis in Crohn’s disease. Inflamm Bowel Dis. 2006; 12: 346-354.

14. von Boyen GB, Reinshagen M, Steinkamp M, Adler G, Kirsch J. Gut inflammation modulated by the enteric nervous system and neurotrophic factors. Scand J Gastroenterol. 2002; 37: 621-625.

15. Laerum OD, Illemann M, Skarstein A, Helgeland L, Ovrebø K, Danø K, et al. Crohn’s disease but not chronic ulcerative colitis induces the expression of PAI-1 in enteric neurons. Am J Gastroenterol. 2008; 103: 2350-2358

16. Kami?ska B, Landowski P, Gonkowski S, Szlagatys-Sidorkiewicz A, Majewski M, Dobosz M, et al. [Analysis of enteral nervous system in children with drug resistant ulcerative colitis]. Med Wieku Rozwoj. 2007; 11: 117-122.

17. Neunlist M, Aubert P, Toquet C, Oreshkova T, Barouk J, Lehur PA, et al. Changes in chemical coding of myenteric neurones in ulcerative colitis. Gut. 2003; 52: 84-90.

18. Yamamoto K, Yamamoto T, Honjo K, Ichioka H, Oseko F, Kishida T, et al. Electrical stimulation with periodic alternating intervals stimulates neuronal cells to produce neurotrophins and cytokines through activation of mitogen-activated protein kinase pathways. Eur J Oral Sci. 2015; 123: 403-408.

19. Dubanet L, Bentayeb H, Petit B, Olivrie A, Saada S, et al. Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas. Br J Cancer. 2015; 113: 934-944.

20. Martins LB, Duarte H, Ferreira AV, Rocha NP, Teixeira AL, Domingues RB. Migraine is associated with altered levels of neurotrophins. Neurosci Lett. 2015; 587: 6-10.

21. Kubanov AA, Katunina OR, Chikin VV. Expression of Neuropeptides, Neurotrophins, and Neurotransmitters in the Skin of Patients with Atopic Dermatitis and Psoriasis. Bull Exp Biol Med. 2015; 159: 318- 322.

22. Brunoni AR, Machado-Vieira R, Zarate CA, Jr., Vieira EL, Valiengo L, Bensenor IM, et al. Assessment of non-BDNF neurotrophins and GDNF levels after depression treatment with sertraline and transcranial direct current stimulation in a factorial, randomized, sham-controlled trial (SELECT-TDCS): an exploratory analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2015; 56: 91-96.

23. da Silveira AB, Lemos EM, Adad SJ, Correa-Oliveira R, Furness JB, D’Avila Reis D. Megacolon in Chagas disease: a study of inflammatory cells, enteric nerves, and glial cells. Hum Pathol. 2007; 38: 1256-1264.

24. da Silveira AB, Freitas MA, de Oliveira EC, Neto SG, LuquettiAO, Furness JB, et al. Neuronal plasticity of the enteric nervous system is correlated with chagasic megacolon development. Parasitology. 2008; 135: 1337-1342.

25. Dias JC. [Globalization, inequity and Chagas disease]. Cad Saude Publica. 2007; 23: 13-22.

26. Lemos EM, Reis D, Adad SJ, Silva GC, Crema E, Correa-Oliveira R. Decreased CD4(+) circulating T lymphocytes in patients with gastrointestinal chagas disease. Clin Immunol Immunopathol. 1998; 88: 150-155.

27. d’Avila Reis D, Lemos EM, Silva GC, Adad SJ, McCurley T, CorreaOliveira R, et al. Phenotypic characterization of the inflammatory cells in chagasic megaoesophagus. Trans R Soc Trop Med Hyg. 2001; 95: 177-178.

28. Bassotti G, Villanacci V, Antonelli E, Morelli A, Salerni B. Enteric glial cells: new players in gastrointestinal motility. Lab Invest. 2007; 87: 628-632.

29. Downing JE, Miyan JA. Neural immunoregulation: emerging roles for nerves in immune homeostasis and disease. Immunol Today. 2000; 21: 281-289.

de Freitas MAR, Segatto N, Remolli PF, de Oliveira EC, Brehmer A, da Silveira AB (2016) Neurotrophin Expression in Chagasic Megacolon JSM Atheroscler 1(3): 1013.

Received : 27 Sep 2016
Accepted : 28 Oct 2016
Published : 01 Nov 2016
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X